ALLERGY IMMUNOTHERAPY MARKET SIZE & SHARE ANALYSIS - GROWTH TRENDS & FORECASTS (2025 - 2030)

Global Allergy Immunotherapy Market Trends and Insights

Growing burden and economic cost of respiratory and food allergies

Untreated allergic disease imposes substantial indirect costs, with European studies showing EUR 2,405 per patient annually compared with EUR 125 for properly managed cases, a nineteen-to-one gap that motivates payer support for disease-modifying options^{[1]Wiley, “Inadequately managed allergies cause significant economic burden in Europe,” sciencedaily.com}. In the United States, food allergies alone create USD 24.8 billion in yearly economic impact including medical expenses, lost productivity and quality-of-life effects. As prevalence climbs past 40% of the global population, health systems view allergen immunotherapy as a cost-saving intervention that can halt progression from rhinitis to asthma. These pressures underpin sustained expansion of the allergy immunotherapy market even as biosimilar price erosion takes hold. Driven by payer interest, providers increasingly initiate early intervention that reduces downstream medication use and emergency visits.

Expedited approvals of SLIT tablets in the US, EU and Japan

Harmonized review pathways shorten development cycles and allow simultaneous launches. ALK’s tree pollen tablet obtained European clearance for children aged 5-17 years in April 2025, widening its treatable base ahead of the 2025/26 season. The FDA’s collaborative path with DBV Technologies on Viaskin Peanut and Japan’s inclusion in accelerated routes provide a trilateral platform that cuts sequential filing costs for smaller firms. Faster access to these standardised tablets enhances patient uptake thanks to predictable dosing and pharmacy supply, supporting momentum in the allergy immunotherapy market. Early convergence is most pronounced for respiratory allergens but sets precedent for food and venom indications.

Inclusion of AIT in value-based care and reimbursement frameworks

Medicare’s designation of allergen immunotherapy as reasonable and necessary, combined with private-payer policies that specify medical-necessity criteria for SLIT, highlights a shift from volume-based to outcome-based remuneration^{[2]Centers for Medicare & Medicaid Services, “Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT),” cms.gov}. Reimbursement structures now reward reductions in rescue medication, fewer emergency visits and better quality-of-life scores, aligning financial incentives with long-term efficacy. Insurers see potential budget relief from preventing escalation to chronic asthma, sustaining investments that lift penetration of the allergy immunotherapy market among eligible patients.

AI-guided personalization of allergen extracts and dosing

Artificial intelligence identifies shared molecular targets such as IL4R, IL5 and JAK proteins, facilitating cross-indication drug design and precise dosing algorithms. Clinical pilots in pediatric milk allergy achieved full tolerance after algorithmically optimized regimens, demonstrating capacity to tailor escalation schedules while curbing adverse events. Tools like AllergenAI screen protein sequences to predict allergenicity, accelerating candidate selection. As digital platforms incorporate continuous data feeds, treatment personalization is expected to lower abandonment and raise real-world effectiveness, reinforcing growth across the allergy immunotherapy market.

Low diagnosis and therapy uptake in low-income regions

Infrastructure gaps constrain adoption: China hosts about 300 million allergic rhinitis sufferers yet fewer than 1% receive immunotherapy, reflecting limited standardized vaccines and scarce trial data tailored to local populations. Similar patterns appear in rural South Asia and Africa, where specialist shortages and travel costs deter patients. Cultural preference for traditional medicine further suppresses demand. Overcoming these barriers will be essential to unlock the full global potential of the allergy immunotherapy market.

Irregular supply of GMP-grade allergen source materials

Seasonal dependence on biological raw materials results in volatile supply and contributes to 27% of drug shortages worldwide. USP 797 sterile compounding rules add cost and limit the number of compliant facilities. Climate-driven changes in pollen patterns further challenge inventory planning, occasionally forcing dose adjustments when switching suppliers. These hurdles restrict consistent product availability and temper expansion of the allergy immunotherapy market until synthetic or recombinant alternatives scale.

Segment Analysis

By Immunotherapy Type: Convenience-centered innovation accelerates EPIT uptake

Subcutaneous Immunotherapy retained 45.55% of 2024 revenue, validating its clinical heritage and extensive physician experience within the allergy immunotherapy market. Yet Epicutaneous Immunotherapy is on track for a 14.25% CAGR to 2030 as Viaskin Peanut reported 67% toddler responders at 12 months and sustained benefit at 36 months. Patient comfort drives preference: EPIT shows 90% compliance in trials versus frequent drop-outs seen with injections.

Growing tablet and drop options advance sublingual immunotherapy, but adverse event profiles have curbed enthusiasm for high-dose oral protocols. Phase III data found 36% of omalizumab recipients tolerated 2,000 mg peanut protein versus 19% with oral therapy, guiding clinicians toward combined or biologic-first strategies. Modified six-injection PQ Grass regimens and ultrasound-guided intralymphatic protocols further illustrate ongoing attempts to shorten courses without sacrificing effectiveness. These innovations collectively sustain growth in the allergy immunotherapy market while diversifying patient options.

Note: Segment shares of all individual segments available upon report purchase

By Allergy Type: Food allergy therapies redefine growth priorities

Food allergy treatments are forecast to expand at 15.15% CAGR, reshaping allocation of R&D capital inside the allergy immunotherapy market. FDA clearance of Xolair for multi-food indications in 2024 enabled 68% of participants to tolerate 600 mg peanut protein compared with 5% on placebo, proving systemic therapy viability. Cross-reactivity strategies also show promise; birch pollen tablets improved related food allergy symptoms in adults, allowing efficient dual-benefit prescribing.

Allergic asthma maintains the largest 2024 share at 36.53%, driven by chronic disease prevalence and established insurance coverage. Rhinitis volumes stay resilient as climate change lengthens pollen seasons. Venom and atopic dermatitis sub-segments continue to attract research into combined microbiome and immunotherapy approaches, supporting broader application breadth. Collectively, these shifts extend the total allergy immunotherapy market size while keeping therapy diversification in motion.

By Formulation: Patch-based delivery challenges injections

Injectable suspensions controlled 55.62% of sales in 2024 due to well-understood preparation and dosing, yet transdermal patches are projected to grow 9.52% CAGR through 2030. Viaskin achieves desensitisation without injections, and skin reactions are typically mild and transient. Nanoparticle carriers add another layer of innovation by protecting allergens and directing them to immune tissues, lowering required doses.

Sublingual tablets gain momentum from tight manufacturing standards that reassure regulators and prescribers alike. Drops retain popularity for pediatric use given the ease of home administration. As maturation of alternative formats continues, the allergy immunotherapy market size linked to non-injection options will increase, diluting reliance on legacy suspensions.

Note: Segment shares of all individual segments available upon report purchase

By Distribution Channel: Digital ecosystems expand patient reach

Retail & hospital pharmacies held 62.72% share in 2024, benefiting from integrated insurance billing and in-clinic prescribing flows. Yet e-commerce/mail-order services are forecast to post 12.22% CAGR, supported by platforms that bundle testing, teleconsultation and direct-to-door delivery within a single user interface. These technology-enabled models lower geographic access barriers and create scalable adherence monitoring.

Direct-to-physician channels remain relevant for patients requiring monitored dose escalation or biologic therapy. Hybrid arrangements that pair virtual follow-up with community pharmacy pickup are emerging, offering flexibility without compromising safety. The continuing pivot to digital channels strengthens the global allergy immunotherapy market by pulling previously untreated consumers into care pathways.

Geography Analysis

North America accounted for 40.72% of 2024 revenue, buoyed by FDA agility exemplified by approvals of Xolair for food allergy and neffy nasal spray for anaphylaxis^{[3]U.S. Food and Drug Administration, “FDA Approves First Medication to Help Reduce Allergic Reactions to Multiple Foods After Accidental Exposure,” fda.gov}. Robust private and public reimbursement, coupled with widespread specialist availability, sustain broad uptake. Commercial launch of neffy generated USD 7.8 million net revenue in Q1 2025, underscoring swift market response.

Asia-Pacific is projected to record a 14.22% CAGR through 2030. China’s 300 million rhinitis patients present the largest untreated cohort and drive policy interest in localized vaccine production. Japan’s fast-track review schemes and mature payer environment ease entry for novel tablets and patches. South Korea and Australia leverage strong diagnostics and patient education, while India’s vast population requires price-sensitive, telehealth-enabled solutions to unlock volume growth.

Europe posts steady gains underpinned by EMA alignment across member states, comprehensive insurance coverage and solid clinical infrastructure. Germany commands the biggest patient base, and Stallergenes Greer’s investment in sales training supports wider Nordic, Italian and Spanish penetration. The United Kingdom advances innovative practice through NHS trials using daily food allergen micro-dosing. Middle East and Africa plus South America reside at earlier adoption stages, yet rising urban income and smartphone penetration foster future expansion via digital distribution. Collectively these regional dynamics reinforce the resilience and breadth of the allergy immunotherapy market.